{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-118064","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.261984+00:00","generated_at":"2026-06-08T03:50:29.392955+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acurx reports Q3 net loss of $3.1M; ibezapolstat Phase 2 shows 96% cure rate, advancing to Phase 3","bullets":["Net loss $3.1M ($0.24/diluted share) vs $3.5M ($0.32) in Q3 2022; cash $7.1M at Sept 30, 2023.","Post-quarter warrant conversion raised $2.2M via ~680,000 shares issued.","Ibezapolstat Phase 2 top-line: 96% (25/26) clinical cure rate at end of treatment; no safety concerns.","Company preparing for End-of-Phase 2 FDA meeting and Phase 3 initiation.","R&D expenses $1.3M in Q3 (down from $1.6M); G&A $1.8M (down from $2.0M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-118064","json":"https://secwatch.observer/filing/0001104659-23-118064.json","markdown":"https://secwatch.observer/filing/0001104659-23-118064.md","text":"https://secwatch.observer/filing/0001104659-23-118064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923118064/0001104659-23-118064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923118064/tm2330757d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:50:29.392955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84b1a9cbd625e57fae84d0157f6bebe2e40051e9","claim":"Acurx Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: net income $3.1 million or $0.24 per diluted share.","evidence_excerpt":"The Company reported a net loss of $3.1 million or $0.24 per diluted share for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923118064/0001104659-23-118064-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$3.1 million or $0.24 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}